Hua Medicine (Shanghai) Ltd.
OTC: HUMDF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Li Chen
- Employees
- 168
- Headquarters
- Shanghai, China
- IPO year
- 2021
- Market cap
- $338.9M
- Website
- https://www.huamedicine.com
Loading HUMDF…
Loading profile data…Frequently asked questions about HUMDF
What does Hua Medicine (Shanghai) Ltd. (HUMDF) do?
Hua Medicine (Shanghai) Ltd. is a clinical-stage pharmaceutical firm specializing in treatments for diabetes, primarily targeting the Chinese market. Its flagship product is Dorzagliatin (also known as HMS5552), an oral medication currently being developed for managing Type 2 Diabetes (T2D). Additionally, the company is advancing Dorzagliatin th...
Where does HUMDF trade?
Hua Medicine (Shanghai) Ltd. (HUMDF) trades on the Other OTC.
What sector is HUMDF in?
Hua Medicine (Shanghai) Ltd. (HUMDF) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Hua Medicine (Shanghai) Ltd.?
Li Chen is the chief executive officer of Hua Medicine (Shanghai) Ltd. (HUMDF).
Where is Hua Medicine (Shanghai) Ltd. headquartered?
Hua Medicine (Shanghai) Ltd. is headquartered in China.
Does HUMDF pay a dividend?
Hua Medicine (Shanghai) Ltd. (HUMDF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did HUMDF go public?
Hua Medicine (Shanghai) Ltd. (HUMDF) completed its initial public offering in 2021.